RT Journal Article
SR Electronic
T1 Treatment of Six COVID-19 Patients with Convalescent Plasma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.21.20109512
DO 10.1101/2020.05.21.20109512
A1 Jin, Can
A1 Gu, Juan
A1 Yuan, Youshu
A1 Long, Qinying
A1 Zhang, Qi
A1 Zhou, Hourong
A1 Wu, Weidong
A1 Zhang, Wei
YR 2020
UL http://medrxiv.org/content/early/2020/06/25/2020.05.21.20109512.abstract
AB Objective To describe the efficacy of convalescent plasma transfusion for COVID-19 patients.Methods This is a retrospective study of 6 COVID-19 patients with convalescent plasma at Guizhou Provincial Jiangjunshan Hospital – a tertial hospital, in Guiyang, Guizhou, China, from January 29, to April 30, 2020; final data of follow-up was May 12, 2020. Through the review of the electronic medical records of Guizhou Jiangjunshan Hospital, clinical data of 6 patients were obtained. Three patients with worsening symptoms after empirical treatment with antivirals were transfused convalescent plasma therapy for the first treatment, while the other three severe or critical COVID-19 patients with rapid progression were transfused. The efficacy of convalescent plasma depends on the relief of symptoms, changes in laboratory indicators and chest imaging abnormalities.Results The PaO2 / FiO2 and lymphocyte count of patients 1, 2 and 3 treated with convalescent plasma treatment for the first treatment period were changed from abnormal to normal. The levels of inflammation markers CRP and IL-6 of the patients decreased significantly. Chest imaging examination showed that the lung lesions gradually subsided. The relapsed patients (No. 4 and No. 6), after using convalescent plasma therapy, turned negative on two consecutive throat swab tests on Day 24 and Day 3, respectively.Conclusions Convalescent plasma treatment of COVID-19 is beneficial for those patients with be difficult to turn to negative or re-positive RT-PCR.Key Points Convalescent plasma treatment of COVID-19 is beneficial for those patients with be difficult to turn to negative or re-positive RT-PCR.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000033056Clinical Protocols http://www.chictr.org.cn/edit.aspx?pid=53859&htm=4 Funding StatementThis study was supported by Science and Technology Support Plan of Guizhou Province in 2019 (Qian Ke He Support [2019] 2834) and Science and Technology Plan of Guizhou Province in 2020 (Qian Ke He Fundamental [2020] 1Z061).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Biomedical Ethics Committee of Affiliated Hospital of Zunyi Medical University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe stated that all the data and materials were true and available in the study. http://www.chictr.org.cn/edit.aspx?pid=53859&htm=4